Entasis Therapeutics Holdings Inc (ETTX) Fundamental Analysis & Valuation

NASDAQ:ETTX • US2936141033

Current stock price

2.19
-0.01 (-0.45%)
Last:

This ETTX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. ETTX Profitability Analysis

1.1 Basic Checks

  • In the past year ETTX has reported negative net income.
ETTX Yearly Net Income VS EBIT VS OCF VS FCFETTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 -10M -20M -30M -40M -50M

1.2 Ratios

Industry RankSector Rank
ROA -117.26%
ROE N/A
ROIC -125.57%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ETTX Yearly ROA, ROE, ROICETTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 -50 -100 -150

1.3 Margins

  • ETTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ETTX Yearly Profit, Operating, Gross MarginsETTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 -200 -400 -600

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. ETTX Health Analysis

2.1 Basic Checks

  • ETTX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • ETTX has more shares outstanding than it did 1 year ago.
  • There is no outstanding debt for ETTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ETTX Yearly Shares OutstandingETTX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 10M 20M 30M 40M
ETTX Yearly Total Debt VS Total AssetsETTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M

2.2 Solvency

  • ETTX has an Altman-Z score of -8.99. This is a bad value and indicates that ETTX is not financially healthy and even has some risk of bankruptcy.
  • There is no outstanding debt for ETTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.99
ROIC/WACC-13.14
WACC9.55%
ETTX Yearly LT Debt VS Equity VS FCFETTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 0 20M -20M 40M -40M 60M 80M

2.3 Liquidity

  • A Current Ratio of 1.65 indicates that ETTX should not have too much problems paying its short term obligations.
  • ETTX has a Quick Ratio of 1.65. This is a normal value and indicates that ETTX is financially healthy and should not expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 1.65
Quick Ratio 1.65
ETTX Yearly Current Assets VS Current LiabilitesETTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. ETTX Growth Analysis

3.1 Past

  • ETTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 28.66%, which is quite impressive.
EPS 1Y (TTM)28.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10.34%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 2.06% on average over the next years.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-11.98%
EPS Next 2Y-3.74%
EPS Next 3Y12.27%
EPS Next 5Y2.06%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ETTX Yearly Revenue VS EstimatesETTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2023 2024 2025 2026 50M 100M 150M 200M
ETTX Yearly EPS VS EstimatesETTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 -1 -2 -3 -4

More info and screens

Find the best growth stocksShow best growing peers

0

4. ETTX Valuation Analysis

4.1 Price/Earnings Ratio

  • ETTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year ETTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ETTX Price Earnings VS Forward Price EarningsETTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -1.28
ETTX Per share dataETTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ETTX's earnings are expected to grow with 12.27% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.74%
EPS Next 3Y12.27%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ETTX Dividend Analysis

5.1 Amount

  • ETTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

ETTX Fundamentals: All Metrics, Ratios and Statistics

Entasis Therapeutics Holdings Inc

NASDAQ:ETTX (7/8/2022, 8:00:02 PM)

2.19

-0.01 (-0.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-27
Earnings (Next)08-09
Inst Owners2.61%
Inst Owner Change-82.85%
Ins Owners49.22%
Ins Owner Change0%
Market Cap104.80M
Revenue(TTM)N/A
Net Income(TTM)-51.70M
Analysts47.5
Price Target2.04 (-6.85%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 6.29
P/tB N/A
EV/EBITDA -1.28
EPS(TTM)-1.12
EYN/A
EPS(NY)-1.17
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS0.35
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -117.26%
ROE N/A
ROCE N/A
ROIC -125.57%
ROICexc N/A
ROICexgc -125.57%
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.65
Quick Ratio 1.65
Altman-Z -8.99
F-Score3
WACC9.55%
ROIC/WACC-13.14
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)28.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10.34%
EPS Next Y-11.98%
EPS Next 2Y-3.74%
EPS Next 3Y12.27%
EPS Next 5Y2.06%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

Entasis Therapeutics Holdings Inc / ETTX Fundamental Analysis FAQ

What is the ChartMill fundamental rating of Entasis Therapeutics Holdings Inc (ETTX) stock?

ChartMill assigns a fundamental rating of 1 / 10 to ETTX.


Can you provide the valuation status for Entasis Therapeutics Holdings Inc?

ChartMill assigns a valuation rating of 1 / 10 to Entasis Therapeutics Holdings Inc (ETTX). This can be considered as Overvalued.


Can you provide the profitability details for Entasis Therapeutics Holdings Inc?

Entasis Therapeutics Holdings Inc (ETTX) has a profitability rating of 1 / 10.